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Abstract: Oxygen and iron are two elements closely related from a (bio)chemical point of 
view. Moreover, they share the characteristic of being indispensable for life, while also being 
potentially toxic. Therefore, their level is strictly monitored, and sophisticated pathways have 
evolved to face variations in either element. In addition, the expression of proteins involved in 
iron and oxygen metabolism is mainly controlled by a complex interplay of proteins that sense 
both iron levels and oxygen availability (ie, prolyl hydroxylases, hypoxia inducible factors, and 
iron regulatory proteins), and in turn activate feedback mechanisms to re-establish homeostasis. 
In this review, we describe how cells and organisms utilize these intricate networks to regulate 
responses to changes in oxygen and iron levels. We also explore the role of these pathways in 
some pathophysiological settings.
Keywords: hypoxia, prolyl hydroxylases, hypoxia inducible factors, iron regulatory proteins, 
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Introduction
Iron and oxygen are two closely related elements: the large amount of iron that is present 
in the earth originated approximately 4.6 billion years ago from an oxygen-dependent 
process occurring during supernova explosions, the thermonuclear disruptions of a 
white dwarf star in which carbon and oxygen fused into radioactive nickel that decayed 
quickly into radioactive cobalt, which subsequently decayed into stable iron (56Fe). 
Recently, proof of this process was provided by the INTEGRAL satellite that detected 
gamma ray lines from the radioactive decay of nickel into iron.1 The interaction of iron 
and oxygen continued during the slow and long (1.5 billion years) accumulation in the 
atmosphere of the oxygen produced by photosynthesizing cyanobacteria that led to the 
present 20.9% atmospheric oxygen content. Over this period of time, living organisms 
adapted to exploit the higher metabolic efficiency of aerobic reactions and the chemical 
reactivity of iron for processes essential for life. In parallel, it has been necessary to 
evolve protection systems against the damage caused by the iron-catalyzed generation 
of highly reactive hydroxyl radicals from the less harmful superoxide and hydrogen 
peroxide (reactive oxygen species) continuously produced by every cell living in aero-
bic conditions.2 To this purpose, a complex regulatory pathway formed by a variety of 
proteins that bind, transport, and store iron has been developed, in order to maintain 
an appropriate iron balance in both the individual cells and the whole body.3
In addition, an adaptive response to hypoxia, both at the cellular and organismal levels 
and in populations living at high altitude, has evolved in order to ensure the delivery 
of appropriate levels of oxygen to tissues. Paradoxically, while activation of hypoxia 
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inducible factors (HIF) confers cellular adaptation to hypoxia, 
in some highlanders (Tibetan and Ethiopians) variants in genes 
of the HIF pathway (eg, EGLN1 and EPAS1 coding for PHD2 
and HIF-2α, respectively, see section: The HIF-hydroxylase 
system controls cellular oxygen homeostasis) that confer a 
hypo-responsiveness to hypoxia seem to have been crucial 
for adaptation to high altitude.4
HIF and IRPs are two 
interconnected sensors of both iron 
levels and oxygen availability
The interaction between oxygen and iron is not limited to 
the oxygen transport function performed by proteins contain-
ing heme iron, such as hemoglobin and myoglobin. In fact, 
the iron regulatory proteins (IRP1 and IRP2) that control 
cellular iron homeostasis and the hydroxylases that control 
the stability and activity of HIF sense both iron levels and 
oxygen availability, and in turn regulate both pathways in a 
coordinate and interconnected way.
The HiF-hydroxylase system controls 
cellular oxygen homeostasis
In this paragraph, we will offer only a brief summary of the 
role of HIF (HIF-1α and HIF-2α) as regulators of oxygen 
homeostasis, a topic comprehensively described in recent 
excellent reviews.5,6 The cells respond to conditions of insuf-
ficient oxygen availability by increasing the amount and 
activity of HIF transcription factors, which induce the expres-
sion of a large number of genes involved in the response 
to hypoxia.5,6 The oxygen-regulated HIF-1α and HIF-2α 
subunits form heterodimers with the constitutively expressed 
HIF-1β subunit and bind hypoxia responsive elements 
(HRE) in DNA regulatory regions that can be far from the 
transcription start site. A third HIF-α (HIF-3α), structurally 
and functionally distinct, is present in humans and mammals, 
but its role and mode of action are not completely clear. One 
reason for this is the presence of alternative splice variants 
coding for at least six isoforms with structural and functional 
differences that complicate the study of HIF-3α. Although 
several studies have led to the view that HIF-3α is a negative 
regulator of HIF-1α and HIF-2α, recent evidence suggests 
that HIF-3α activates a distinct transcriptional response to 
hypoxia, at least in zebrafish.7
The targets of HIF include genes with a direct role in 
the adaptation to hypoxia, as well as regulatory molecules 
with a secondary effect on gene expression, such as induc-
tion of transcriptional repressors that result in decreased 
expression of many genes under hypoxic conditions. 
Notably, genes coding for proteins directly or indirectly 
involved in iron metabolism are among the variety of HIF 
target genes (Table 1).8 Another connection between the 
hypoxic response and iron metabolism is represented by 
the iron requirement of the prolyl hydroxylases (PHDs) that 
regulate HIF-α stability. PHDs are members of a family 
of 2-oxoglutarate-dependent dioxygenases whose activity 
requires 2-oxoglutarate and oxygen as obligatory substrates 
and non-heme ferrous iron as cofactor.9,10 In addition to 
other important functions, such as collagen biosynthesis, 
these enzymes play an important role in gene expression. In 
fact, they are involved in the control of both epigenetic (eg, 
DNA demethylation and histone lysine demethylation) and 
transcriptional (eg, HIF) regulation. PHDs catalyze prolyl 
hydroxylation in the oxygen-dependent degradation domains 
of HIF-α. After this modification, the affinity of HIF-α for 
the E3 ubiquitin ligase von Hippel-Lindau (VHL) protein 
increases several hundred fold, thereby leading to HIF-α 
degradation by the proteasome (Figure 1).9,10 The mechanism 
by which PHDs act as hypoxia sensors is both efficient and 
sensitive to changes in oxygen availability, such that under 
normoxia the inducible HIF-α are extremely short lived, but 
as oxygen levels fall slightly, the decrease in PHDs activ-
ity allows HIF-α levels to rise and the hypoxic response to 
start. PHDs are also sensors of energy metabolism, as the 
Krebs cycle intermediates 2-oxoglutarate and succinate 
and fumarate are an activator or inhibitors, respectively, of 
2-oxoglutarate-dependent dioxygenases enzymes. Moreover, 
PHDs activity is dependent on the availability of ferrous iron, 
and therefore, HIF-dependent transcription is also induced 
by iron deprivation, even under normoxia.9,10 Asparaginyl 
hydroxylation of HIF-1/2α by factor inhibiting HIF, which 
Table 1 Proteins of iron metabolism regulated by HiF
Proteins Functions
HIF-1 dependent
Transferrin iron transport
Transferrin receptor 1 iron uptake
Ceruloplasmin iron oxidation
Ferrochelatase Heme synthesis
Furin Regulation of iron homeostasis
Heme oxygenase Heme catabolism
Matriptase2 Regulation of iron homeostasis
HIF-2 dependent
DMT1 iron uptake
DcytB iron reduction
epo erythropoiesis
Ferroportin iron export
Frataxin Assembly of iron sulfur-cluster
Abbreviations: DMT1, divalent metal transporter; epo, erythropoietin; HiF, 
hypoxia inducible factors.
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inhibits their transactivation activity, represents an additional 
mechanism preventing the hypoxic response when sufficient 
oxygen and cofactors are available.6
Despite extensive studies, the respective role of HIF-1α 
and HIF-2α has not been fully clarified. They bind the same 
HRE in vitro and share an overlapping set of target genes, 
but they also activate the transcription of distinct genes. For 
example, both HIF-α bind the HRE of erythropoietin (Epo), 
but selective inactivation in mice revealed that only HIF-2α 
is important for Epo production in vivo.11
In this context, the activity of the various components 
of the HIF pathway can be modulated by various factors, 
including tissue-specific expression and oxygen sensing. In 
relation to the interdependence of iron and oxygen homeo-
stasis covered in this review, we would like to point out the 
direct regulation of HIF-2α mRNA stability by iron (see 
section: The IRE/IRP regulatory pathaway controls cellular 
iron homeostasis).
The iRe/iRP regulatory pathway controls 
cellular iron homeostasis
The challenging task of maintaining intracellular iron 
levels sufficient for essential cellular functions, but as low 
as possible to avoid reactive oxygen species formation, is 
mainly performed by IRP1 and IRP2, which tightly control 
intracellular iron metabolism by regulating at the post-
transcriptional level the expression of genes coding for 
proteins involved in iron uptake, utilization, storage, and 
export.8,12–14
All these proteins are coded by mRNAs with conserved 
25–30 nucleotide-long sequences in their untranslated 
regions that are able to form stem-loop structures called iron 
responsive elements (IREs).
IRP1 is a “moonlighting” protein that can perform 
two entirely different functions; when sufficient iron is 
available, IRP1 can assemble a [4Fe-4S] cluster becom-
ing the cytosolic counterpart of mitochondrial aconitase 
and catalyzing the conversion of citrate and isocitrate, 
a function that may affect NADPH levels and lipid bio-
synthesis.15 Conversely, in conditions of iron deficiency, 
IRP1 cannot form the cluster and the apoform is able to 
bind IREs, and thus control the expression of a variety of 
mRNAs (Figure 2).
IRP2, which is highly homologous to IRP1, binds IRE 
motifs with affinity and specificity similar to that of IRP1, 
but is controlled by a different mechanism. In fact, IRP2 
is not able to assemble a [4Fe-4S] cluster, and hence is not 
regulated by the switch between an apoform and a cluster-
containing form; conversely, the protein accumulated in iron-
deficient cells and in iron-replete cells is rapidly targeted for 
proteasomal degradation by an E3 ubiquitin ligase complex 
that comprises FBXL5 (see section: The iron-oxygen axis: 
regulation at the cellular level).16
When iron inside the cell is scarce, active IRPs bind to 
IREs and stabilize the mRNA for transferrin receptor (TfR1) 
and divalent metal transporter DMT1, thus increasing the 
uptake of both transferrin-bound and unbound iron, while 
also decreasing translation of mRNAs for the iron storage 
HERC2
Fe + O2
Fe + O2
FBLX5 FBLX5
FBLX5
NCOA4 NCOA4
CITED2 CITED2
IRP2 IRP2
HIFα HIFα No hypoxic response
Cellular iron
availability
Hypoxic response
Ferritin
(less autophagic
degradation)
(less degradation)
IRP2
Proteasomal
degradation
Figure 1 Different levels of iron and oxygen promote the proteasomal degradation of key regulatory proteins of iron and oxygen metabolism.
Notes: when iron and oxygen are plentiful, PHD-dependent hydroxylation targets for proteasomal degradation HiF-α, whereas FBXL5 accumulates, binds, and targets 
to degradation of iRP2 and CiTeD2. Conversely, the lack of iron and/or oxygen leads to FBXL5 ubiquitination and degradation by the proteasome, thus allowing iRP2 to 
function as a regulator of iron homeostasis. HeRC2 is responsible for the basal proteasomal degradation of FBXL5 at the steady state, but whether its activity is modulated 
by changes in iron and oxygen availability has not been defined (dotted arrows). Moreover, HERC2 induces iron-dependent proteasomal degradation of NCOA4, thus, 
preventing ferritin destruction in the autophagosome.
Abbreviations: HiF, hypoxia inducible factors; iRP, iron regulatory protein.
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Figure 2 Differential iron- and oxygen-dependent regulation of iRP activity.
Notes: In iron-depleted cells, IRP1 (A) and IRP2 (B) bind to IRE, hence inhibiting mRNA translation or degradation, whereas high iron availability converts IRP1 into the 
inactive apoform and promotes iRP2 degradation, thus resulting in loss of iRP-binding activity and an opposite effect on gene expression. Hypoxia has a different effect on the 
two iRPs: inhibition of iRP1-binding activity and stabilization of iRP2.
Abbreviations: iRP, iron regulatory protein; iRe, iron responsive element.
protein ferritin and the iron exporter ferroportin. This coordi-
nated regulation eventually enhances iron availability within 
the cell. Conversely, in iron-replete cells, the IRE-binding 
activity of both IRPs is decreased, resulting in efficient 
translation of ferritin and ferroportin mRNAs and lower 
stability of TfR1 and DMT1 mRNAs, eventually increasing 
iron sequestration and release over uptake (Figure 2).
Targeted deletion of either IRPs has extended our knowl-
edge of their respective role and importance. Embryonic 
lethality in mice lacking both IRPs17 showed that the IRP/
IRE regulatory system is vital. However, the two IRPs can 
compensate for each other, as expression of either IRP1 or 
IRP2 is sufficient for life. Early studies found mild hematopoi-
etic defects and late-onset neurodegeneration in Irp2−/− mice, 
whereas mice lacking IRP1 were apparently normal.8,12–14 In 
line with these findings showing a dominant role for IRP2 in 
the regulation of iron homeostasis in mice, analysis of the com-
parative expression of the two IRPs indicated that IRP2 is the 
major regulator of intracellular iron metabolism in humans.18 
However, more recent results showed an important role for 
IRP1 in the control of the IRE-containing mRNA for erythroid 
aminolevulinate synthase in anemic zebrafish.19 Moreover, 
it appears that the IRE in HIF-2α mRNA is predominantly 
bound by IRP1, as mice with deletion of IRP1 maintained on 
a low iron diet have derepressed HIF-2α expression that leads 
to pulmonary hypertension and polycythemia.20
The iron–oxygen axis: regulation at 
the cellular level
Both IRPs are regulated by multiple factors in addition to 
iron, including oxygen tension, which differentially controls 
their binding activity (reviewed and discussed in Recal-
cati et al,8 Pantopoulos et al,12 Zhang et al,13 Kühn,14 and 
Cairo and Recalcati21). Most studies suggest that hypoxia 
decreases IRP1 binding to IREs, and results in IRP1 acquir-
ing aconitase activity whereas lack of oxygen increases IRP2 
activity (Figure 2).8,21 In this context, a key role is played 
by FBXL5, a recently identified and characterized protein 
that is regulated in an iron- and oxygen-dependent manner 
thanks to an hemerythrin-like domain (Figure 1).16 When 
iron and oxygen are fully available, FBXL5 levels in the 
cell increase promoting IRP2 (and apo IRP1) proteasomal 
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degradation. On the other hand, lack of iron, which impairs 
the assembly of the di-iron center in the hemerythrin-like 
domain, or hypoxia leads to FBXL5 polyubiquitination and 
degradation by the proteasome, thus stabilizing IRP2 and 
increasing iron availability. A recent study demonstrated that 
FBXL5 itself is constitutively targeted to ubiquitin-dependent 
proteasomal degradation through interaction with HERC2,22 
a protein involved in the response to DNA damage. As iron 
is a cofactor of several DNA repair proteins, these findings 
reveal an interesting new link between iron and an essential 
function required for cell survival.
The effects of hypoxia on IRPs binding activity are not 
the only link between oxygen and iron homeostasis. As 
reported above, the lack of oxygen and/or iron inhibits the 
hydroxylation process that results in proteasomal degrada-
tion of HIF-1/2α, thereby increasing protein stability and 
transcriptional capacity.5,6
Moreover, the finding of a functional 5′ IRE in the mRNA 
for HIF-2α showed the existence of another physiologically 
relevant connection between oxygen and iron sensing.13,23 In 
normoxia, active IRP1 represses basal HIF-2α translation, 
whereas in hypoxic conditions the IRP1/IRE interaction is 
impaired and HIF-2α is efficiently translated, thus suggest-
ing that IRP1 acts as a direct or indirect sensor of hypoxia. 
In hypoxia, the combination of increased HIF-2α mRNA 
translation due to impaired IRP1-binding activity and inhib-
ited HIF-2α degradation leads to a strong increase in HIF-2α 
protein levels (Figure 3). Cellular iron deficiency hampers 
PHD activity as well, but also increases IRP1 activity, thus 
repressing HIF-2α translation. This suggests a negative feed-
back control of the HIF-mediated response when iron levels 
are low, in order to fine tune iron availability and utilization. 
This may be particularly relevant to modulate the expression 
of Epo, which is a major target of HIF-2α,11,24 thus potentially 
keeping in balance the rate of red blood cells production with 
iron availability. On the other hand, the demonstration that 
hypoxia and iron metabolism are coordinately regulated also 
in Caenorhabditis elegans,25 which does not have a circula-
tory system, suggests that this pathway has a role that extends 
beyond erythropoiesis.
The role of IRP1 and IRP2 in the response to hypoxia 
has not been fully established; however, while not ruling 
out the possibility that endogenous IRP2 binds to HIF-2α 
IREs, the fact that IRP1 binds the IREs in HIF-2α mRNA 
challenges the concept (inferred by evidence that IRP2 is 
the major IRE-binding protein at physiological [3%–5%] 
oxygen tension)26 that IRP2 has a prominent role in the 
response to hypoxia. However, there is a possible inter-
pretation for the differential response of the two IRPs to 
hypoxia. At low oxygen levels, in which the 4Fe-4S cluster 
of IRP1 is assembled promptly and IRP2 is stable, IRP2 is 
the main regulator of the translation of IRE-bearing mRNAs. 
Conversely, high oxygen concentrations result in stabiliza-
tion of FBXL5 that binds IRP2 and induces its degradation, 
but the apoform of IRP1 can bind IREs and control iron 
balance. These mechanisms are expected to confer the cell 
the capacity to effectively regulate iron metabolism over a 
wide range of oxygen levels.
Notably, it has been recently shown that FBXL5 targets 
to proteasomal degradation CITED2, a nuclear protein that 
limits HIF transcriptional activity by competing for the coact-
ivator CBP/p300.27 It seems therefore that when oxygen and 
iron are available, higher levels of FBXL5 lead to a decrease 
in CITED2, ultimately favoring HIF-dependent transcription 
(Figure 1). Although the meaning of this mechanism in the 
response to hypoxia remains to be established, this finding 
represents a novel additional link between iron and oxygen 
homeostasis.
Recent data point out an increasingly relevant role of 
mechanisms determining protein stability in intracellular 
iron metabolism (Figure 1). For example, the levels of 
NCOA4, which targets ferritin to autophagic turnover and 
HIF-2α mRNA HIF-2α protein
Hypoxia
IRP1 activity
PHD activity
Iron
deficiency
Figure 3 Hypoxia activates two mechanisms to increase the amount of HiF-2α protein: derepression of HiF-2α translation through impaired binding of iRP1 to its iRe and 
prevention of HiF-2α degradation by inhibition of prolyl hydroxylase (PHD) activity.
Notes: Iron deficiency has the same effect on PHD activity, but also activates IRP1-binding capacity, thereby inhibiting HIF-2α translation.
Abbreviations: HiF, hypoxia inducible factors; iRP, iron regulatory protein; iRe, iron responsive element.
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thus affects iron availability at both the cellular and systemic 
levels, are regulated by HERC2-mediated proteasomal 
degradation.28 Clearly, in this context, the proteasome is 
a key player; therefore, one possible question is how iron 
homeostasis could be affected by changes in proteasomal 
activity, which can occur in a variety of pathophysiologic 
conditions including the immune response, neurodegenera-
tive diseases, and cancer.29 For instance, will proteasomal 
inhibition lead (directly) to a higher amount of IRP2 or 
(indirectly) to a decrease in IRP2 levels because of FBXL5 
stabilization? Although this problem has not been experi-
mentally addressed in a specific way, a couple of recent 
papers provide some information. Multiple myeloma cell 
lines exposed to bortezomib, a proteasome inhibitor in use 
for treatment of this type of tumor, showed a 50% reduction 
in IRP-binding activity,30 an effect that the authors attrib-
uted to oxidative stress-mediated IRP2 degradation, but 
could well be the result of lower proteasomal degradation 
of FBXL5. Conversely, higher IRP2 levels were found in 
neuronal cells exposed to a different proteasomal inhibitor 
(lactacystin).31 These contrasting results may depend on the 
remarkably different experimental models, but also suggest 
that further studies are needed to investigate the role of the 
proteasome in cellular iron metabolism.
The rapid emergence of microRNAs (miRNAs) as key 
regulators of gene expression in a variety of biological pro-
cesses expanded recently to the connection between iron and 
oxygen homeostasis. miRNA-210 was identified as a HIF 
target, induced by both hypoxia and iron deprivation,32 which 
regulates iron homeostasis through a complex mechanism. In 
fact, miRNA-210 directly inhibits TfR1 expression by direct 
binding to TfR1 mRNA. However, miRNA-210 concurrently 
suppresses ISCU, a protein involved in iron–sulfur cluster 
formation, thus switching IRP1 to the RNA-binding apoform, 
and leading to TfR1 mRNA stabilization. The net result of 
these contrasting mechanisms was decreased transferrin 
internalization (and possibly iron uptake) in miRNA-210-
transfected breast cancer cells. On the other hand, previous 
studies have shown that TfR1 transcription is induced by 
hypoxia and iron deficiency.33–35 Therefore, it seems that 
numerous mechanisms of regulation of gene expression 
cooperate to amplify the range of control and response to 
stimuli. These recent advances support previous evidence 
indicating that precise regulation of TfR1 expression, and 
more generally of iron levels, is a key for cell activity, and 
probably depends on individual cell needs and specificities. 
HIF-1-dependent transcriptional upregulation may cooperate 
with IRP-dependent post-transcriptional control to expand 
the extent of response of iron homeostasis genes to oxygen or 
iron shortage. In fact, iron chelation induced TfR1 expression 
less efficiently in HIF-1-deficient hepatoma cells, which only 
depend on IRP-mediated upregulation, than in their wild-type 
counterpart,34 and is strongly induced in VHL-deficient renal 
carcinoma cells that overexpress HIF-1.36
The iron–oxygen axis: regulation at 
the systemic level
The two hormones most important to regulate iron and 
oxygen homeostasis at the systemic level are hepcidin and 
Epo, respectively. Hepcidin controls body iron balance by 
downregulating ferroportin, thus stopping iron efflux from 
duodenal and reticuloendothelial cells.37 Given their related 
physiological function, the idea that Epo could directly 
regulate hepcidin was attractive and initially supported 
by experimental data. For example, under conditions of 
elevated erythropoiesis, such as hypoxia or anemia, the 
enhanced iron absorption to face the higher demand of 
erythropoietic cells is accompanied by a strong inhibition of 
hepcidin expression.38,39 Therefore, the possibility of a direct 
effect of Epo on hepcidin has been explored. Indeed, Epo 
administration in mice (reviewed by Kautz and Nemeth39) 
and humans40,41 resulted in strong repression of hepcidin 
synthesis. Moreover, early studies found a direct repression of 
hepcidin transcription in Epo-treated cell lines.42,43 However, 
the idea of a direct effect of Epo was challenged by studies 
showing that administration of Epo to mice with damaged 
bone marrow due to exposure to cytotoxic agents or irradia-
tion did not result in hepcidin suppression.44 Furthermore, it 
has been demonstrated that increasing liver iron content can 
stimulate hepcidin expression in conditions of permanently 
high Epo serum levels.45 More recently, the inhibitory effect 
of Epo on hepcidin synthesis was observed in mice lacking 
Epo receptor expression in hepatic cells, allowing us to 
show that the direct binding of Epo to liver receptors is not 
necessary to suppress hepcidin.46 In line with this conclusion, 
the erythroid factor erythroferrone (ERFE), which hinders 
hepcidin expression under conditions of high erythropoietic 
activity, was recently identified.47 Altogether, the available 
data indicate that the role of Epo is to stimulate the synthesis 
of ERFE in erythroblasts, which eventually downregulates 
hepcidin production in the liver (Figure 4).
Similarly, it was initially proposed that the increased lev-
els of HIF-1α present in livers of iron-deficient mice might 
repress hepcidin transcription.48 However, subsequent studies 
using liver-restricted deletion of various components of the 
HIF complex49,50 did not confirm a direct transcriptional 
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suppression of hepcidin, and showed that the real role of HIF 
in this context is to induce Epo. The consequent stimulation 
of erythropoiesis then leads to hepcidin inhibition (Figure 4). 
In line with these findings, hepcidin was not suppressed in 
Ethiopians living at high altitude, who do not have a higher 
erythropoietic drive,51 as these populations chronically 
adapted to hypoxia by a pattern not involving increased 
hemoglobin concentration.4 Although in vivo the effect of 
hypoxia on hepcidin is probably indirect, several studies 
reported that activation of HIF by hypoxia, iron chelation, 
or PHDs inhibitors resulted in hepcidin downregulation in 
cultured cells. Also in this case, the effect appears to be 
indirect, because proteins that negatively control hepcidin 
expression are induced by HIF (Table 1). Iron-mediated 
hepcidin induction depends on the assembly on the cell 
surface of a complex consisting of bone morphogenetic 
proteins (BMPs), in particular BMP6, their receptors and 
hemojuvelin, a membrane protein that functions as a co-
receptor for BMPs.37 Hemojuvelin is cleaved by two pro-
teases, Matriptase2 and furin, resulting in the interruption of 
the hepcidin activation pathway and the release of a soluble 
form that acts as a decoy molecule for BMPs, respectively. 
The demonstration that expression of both Matriptase252 
and furin53,54 is increased in hypoxia via HIF-1/2α may thus 
explain the hepcidin downregulation found in cell culture 
experiments. Recently, it has been shown that hypoxia inhib-
its hepcidin expression by a novel pathway involving platelet 
derived growth factor-BB.55 This growth factor is increased 
by hypoxia and regulates hepcidin by interfering with the 
CREB and CREB-H signaling pathways. As platelet derived 
growth factor-BB is stored in several cell types (eg, platelets) 
and promptly released in response to Epo,56 this finding may 
explain that even low-dose Epo injections in humans lead 
to early and considerable decrease in hepcidin levels that 
preceded any change in potentials mediators.40,41,57
Implications in pathophysiology
The IRP–HIF axis is important for various functions of spe-
cific tissues and organs, and its disruption is involved in sev-
eral pathophysiological settings, for example erythropoiesis, 
which has been recently reviewed elsewhere.13,58 Here, we 
will focus on the intestine, the adipose tissue, and the lungs.
iron/oxygen sensing and duodenal  
iron absorption
A number of recent studies provided convincing evidence 
that, in the context of duodenum, which is a key for iron 
absorption, the IRP 1/HIF-2α axis plays a predominant role. 
Iron deficiency specifically induced intestinal HIF-2α,59 and 
intestine-restricted inactivation indicated that HIF-2α is 
required to activate the reductase DcytB and the iron trans-
porters DMT1 and ferroportin, and increase iron absorption 
in the gut of mice kept on an iron-deficient diet.59–61 Notably, 
it has been shown that dysregulation of the HIF-2α–iron axis 
in absorbing enterocytes plays a role in animal models of both 
primary50 and secondary62 iron overload. Moreover, experi-
Hypoxia
Epo
rEpo
ERFE
HIF-2α Hepcidin
Iron absorption
Figure 4 Mechanisms of hepcidin downregulation by hypoxia and epo. 
Notes: endogenous epo produced by the kidney in response to hypoxia in a HiF-2α-dependent way or exogenous recombinant Epo (rEpo) stimulates erythropoiesis. 
Erythroid cells in the bone marrow produce erythroferrone (ERFE) that then leads to hepcidin inhibition and consequent increase in iron absorption.
Abbreviations: epo, erythropoietin; HiF, hypoxia inducible factors.
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ments in mice with IRP1 inactivation and increased duodenal 
HIF-2α expression confirmed that the IRP 1/HIF-2α axis 
coordinates duodenal iron absorption according to systemic 
oxygen and iron availability.63
However, recent studies showing that FBXL5 also plays 
a relevant role at the systemic level, including the gut (see 
review Ruiz and Bruick16), led to reappraisal of the role 
of IRP2 in this context. Regulation of IRP-mediated iron 
homeostasis is disrupted in mice lacking FBXL5, and the 
unregulated IRP2 expression results in embryonic lethality 
due to iron overload in the early placenta. Mice with condi-
tional deletion in the liver showed hepatic iron accumulation 
and died with acute liver damage when fed an iron-enriched 
diet.64 Intriguingly, despite liver overload, these mice express 
inappropriately low hepcidin levels, possibly because of 
impaired BMP6 signaling, and thus present systemic iron 
overload. Moreover, FBXL5 seems to have a special role in 
the intestine, as mice heterozygous for FBXL5 deletion fed 
an iron-deficient diet are able to maintain normal hematologi-
cal values and avoid iron deficiency anemia by increasing 
DMT1-mediated iron absorption.
Role of iron and hypoxia in obesity
Both iron and oxygen homeostasis are modified in obesity. 
Animal studies have demonstrated that adipose tissues 
become hypoxic in obesity and, despite HIF-2α protective 
role, the consequent HIF signaling (mainly mediated by 
HIF-1α) contributes to the development of obesity-associated 
inflammation, insulin resistance, and other metabolic dis-
orders that are strongly associated with obesity.65,66 The 
modifications of iron metabolism in obesity are multifari-
ous and more difficult to put in a coherent framework, with 
strong differences between cell autonomous and systemic 
regulation.67 On the one hand, obese subjects often present 
body iron deficiency, and possibly anemia, probably because 
the chronic and low-grade inflammation that characterizes 
obesity68 leads to hepcidin upregulation and decreased 
circulating iron availability.69 On the other hand, in adipose 
tissue, the picture is more complex, as iron overload may 
play an important role in at least two cell types of obese 
adipose tissue: adipocytes and macrophages. Iron is required 
for adipogenesis (and adipocyte tissue expansion), probably 
because these cells are rich in mitochondria, which are the 
major iron sink of the cell.70,71 However, excess iron in adi-
pocytes leads to decreased adiponectin release and impaired 
adipocyte insulin sensitivity, resulting in compromised sys-
temic glucose tolerance.70,72 Therefore, in adipocytes, like 
in every other body cell, an optimal level of iron is required 
for homeostasis. Adipose tissue also contains macrophages 
that are mainly polarized toward a M2 anti-inflammatory 
phenotype in lean subjects, whereas in obesity the number 
of macrophages is greatly increased, and their polariza-
tion is shifted to the M1 classically activated phenotype.73 
Interestingly, macrophage subtypes not only differ for the 
expression of classical inflammatory markers, but also have 
profound differences in iron handling.74 M1 macrophages 
are characterized by increased iron levels, whereas M2 
macrophages have a pattern of gene expressions that favors 
uptake of heme iron and ferroportin-mediated iron release.75 
As HIF-1α and HIF-2α have been mainly related to M1 
and M2 phenotypes, respectively,76 the lower iron content 
that characterizes M2 macrophages is expected to favor 
HIF-2α stabilization and activity, with a favorable outcome 
in obesity. In fact, activated macrophage HIF-2α will relieve 
adipose tissue inflammation and insulin resistance.77 These 
data reveal another aspect of the complex interplay between 
iron and oxygen homeostasis and highlight its importance 
in relevant pathologies. However, the situation may be more 
complicated because the distinction of macrophages in the 
M1 and M2 subclasses is probably an oversimplification,78 
and indeed M2-like macrophages with either low or high 
iron content have been isolated from adipose tissue.79
Role of iron in hypoxia-dependent 
pulmonary hypertension
Both hypoxia and iron have been demonstrated to play a key 
role in pulmonary hypertension, a common clinical problem 
characterized by progressive pulmonary vasculature remodel-
ing leading to increased pulmonary arterial pressures.80
Both animal models, in which heterozygous deletion or 
activating mutation of HIF-α genes leads to protection from 
pulmonary hypertension and higher sensitivity to hypoxia, 
respectively, and a human genetic condition, Chuvash poly-
cythemia, in which hypoxia sensing is increased because the 
VHL protein is inactive, provided a strong demonstration 
of the role of the HIF pathway in pulmonary hypertension 
(discussed in Zhang et al13).
Several studies have reported that iron deficiency may 
cooperate in the activation of HIF triggered by the condi-
tions of persistent or intermittent hypoxia that are associated 
with pulmonary hypertension. Indeed, increasing iron bio-
availability by intravenous iron loading effectively reversed 
the hypertensive response of the pulmonary vasculature to 
hypoxia.81 The effect of intravenous iron on the pulmonary 
circulation in human studies was observed both under 
laboratory conditions (normobaric hypoxia) and in subjects 
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exposed to high altitude hypobaric hypoxia. Given the high 
prevalence of both nutritional and functional iron deficiency 
(in chronic diseases characterized by cytokine-induced iron 
sequestration in the reticuloendothelial compartment), the 
effect of iron status on oxygen sensing and hypoxia-induced 
pulmonary vasoconstriction would be potentially significant 
for human health.
Notably, mice with IRP 1 inactivation and consequent 
unrestricted HIF-2 activity develop spontaneous pulmonary 
hypertension, thus underscoring the physiological importance 
of the overlap between oxygen and iron sensing.20
Candidate HIF-dependent genes that may contribute 
to the development of hypoxic pulmonary hypertension in 
humans include endothelin and proteins involved in sodium 
and potassium transport. Interestingly, a recent study showed 
that hypoxia elevates miR-210, which in turn represses its 
target ISCU1/2 and downregulates Fe-S cluster formation, 
thus leading to mitochondrial dysfunction and promoting 
pulmonary hypertension.82 Therefore, iron deficiency can 
act both by impairing PHDs activity and by preventing Fe-S 
cluster assembly.
Conclusion
Recent results have advanced the identification of strong 
associations between iron metabolism and oxygen 
homeostasis. However, our understanding of this complex 
interplay remains incomplete. Further studies will clarify 
the mechanistic relationships between these pathways and 
their relevance in pathophysiological conditions and disease, 
possibly paving the way for more advanced therapeutic 
approaches aimed at re-establishing iron and/or oxygen 
homeostasis in clinical settings.
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